title: Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome.
abstract: We have compared the outcomes of 87 patients with acute myelogenous leukemia (AML) and myelodysplasia (MDS) receiving matched sibling transplants with stem cells from peripheral blood (blood cell transplant, BCT) or bone marrow (BMT). In good risk patients (AML in CR1) granulocytes recovered to 0.5 x 10(9)/l a median of 14 days after BCT compared with 19 days after BMT (P < 0.0001). For patients with poor risk disease (AML beyond CR1 and MDS) corresponding figures were 16 vs 26 days (P < 0.0001). Platelet recovery to 20 x 10(9)/l was also faster after BCT (good risk 12 vs 20 days, P < 0.0001; poor risk 17 vs 22 days, P = 0.04). Red cell transfusions were unaffected by cell source, but BCT recipients required less platelet transfusions (good risk 1 vs 5, P = 0.002; poor risk 5 vs 11, P = 0.004). Blood cell transplants resulted in more chronic GVHD (86% vs 48%, P = 0.005) and a significantly higher proportion of recipients with KPS of 80% or less (48% vs 5%, P = 0.004). Disease-free survival at 4 years was 23% for both groups of poor risk patients but outcome in good risk patients was better after BCT (93% vs 62%, P = 0.047) related mainly to less relapse. While disease-free survival may be better after BCT than BMT for AML in CR1, quality of life may be relatively impaired.
authors.affiliation: Alberta Bone Marrow Transplant Program, Foothills Hospital, Edmonton, Canada.
authors.forename: J A
authors.initials: JA
authors.lastname: Russell
authors.forename: L
authors.initials: L
authors.lastname: Larratt
authors.forename: C
authors.initials: C
authors.lastname: Brown
authors.forename: A R
authors.initials: AR
authors.lastname: Turner
authors.forename: A
authors.initials: A
authors.lastname: Chaudhry
authors.forename: K
authors.initials: K
authors.lastname: Booth
authors.forename: R C
authors.initials: RC
authors.lastname: Woodman
authors.forename: J
authors.initials: J
authors.lastname: Wolff
authors.forename: K
authors.initials: K
authors.lastname: Valentine
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: J D
authors.initials: JD
authors.lastname: Ruether
authors.forename: B A
authors.initials: BA
authors.lastname: Ruether
authors.forename: J
authors.initials: J
authors.lastname: Klassen
authors.forename: A R
authors.initials: AR
authors.lastname: Jones
authors.forename: E
authors.initials: E
authors.lastname: Gyonyor
authors.forename: M
authors.initials: M
authors.lastname: Egeler
authors.forename: J
authors.initials: J
authors.lastname: Dunsmore
authors.forename: S
authors.initials: S
authors.lastname: Desai
authors.forename: M J
authors.initials: MJ
authors.lastname: Coppes
authors.forename: T
authors.initials: T
authors.lastname: Bowen
authors.forename: R
authors.initials: R
authors.lastname: Anderson
authors.forename: M C
authors.initials: MC
authors.lastname: Poon
mesh_terms: D000293:Adolescent; D000328:Adult; D016913:Blood Component Transfusion; D001782:Blood Donors; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D006085:Graft Survival; D006086:Graft vs Host Disease; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D011788:Quality of Life; D012008:Recurrence; D012801:Sibling Relations; D015996:Survival Rate; D014184:Transplantation, Homologous
chemical_list: D016179:Granulocyte Colony-Stimulating Factor